Asarina Pharma AB (publ) Q2 2022 Report released
CEO Peter Nordkild: “We are pleased to report continued progress in our Phase II study in Sepranolone for the treatment of Tourette in the second… Read More »Asarina Pharma AB (publ) Q2 2022 Report released